Another Success for BioLineRx: Positive Results From Phase I/II Trial of BL-5010 for Non-Surgical Removal of Skin Lesions JERUSALEM, Dec. 31, 2010 (GLOBE NEWSWIRE) -- BioLineRx (TASE:BLRX) announces receipt of positive results from the Phase I/II clinical trial of BL-5010, a novel formulation for the non-surgical removal...

EAGLE Trial Signals Breakthrough in the Treatment of Schizophrenia BioLineRx's BL-1020 significantly improves cognitive function in patients with schizophrenia These findings indicate BL-1020 could become the drug of choice for ...

BioLineRx Announces Positive Topline Results for BL-1020, a First in Class GABA Enhanced Antipsychotic for the Treatment of Schizophrenia JERUSALEM, Israel, Sept. 14, 2009 (GLOBE NEWSWIRE) -- BioLineRx (TASE:BLRX) announced today topline results from its phase 2b EAGLE (Effective Antipsychosis via GABA Level Enhancement) study assessing...